ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

12 links0 made here, not in the record12 judgments2 judges (the rules as one: Rule based)0 record changes seen
Claude Opus 5.5Rule based
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT05535738Using a Contact DermatitisModel With BiologicMedications to Study SkinInflammationWei-Che KoPhase 2/Phase 3 · active not rRECORDThe record itselfVersions seen nightly since Sep 25, 2…›No new version seen since tracking began Sep 25, 2026.CONDITIONSDermatitisThe registry's MeSH filing›No judgment recorded. Shown as the registry files it.Dermatitis, Allergic ContactThe registry's MeSH filing›As of now · Rule based · Main conditionMain conditionDRUGSSquaric acid dibutyl esterIntervention entry›Nov 18 · Rule based · BackgroundBackgroundDupilumabIntervention entry›Nov 4 · Claude Opus 5.5 · TestedNov 18 · Rule based · BackgroundTestedAdalimumabIntervention entry›Nov 18 · Rule based · BackgroundBackgroundUstekinumabIntervention entry›Nov 18 · Rule based · BackgroundBackgroundGuselkumabIntervention entry›Nov 18 · Rule based · BackgroundBackgroundCanakinumabIntervention entry›Nov 18 · Rule based · BackgroundBackgroundSarilumabIntervention entry›Nov 18 · Rule based · BackgroundBackgroundTriamcinolone AcetonideIntervention entry›Nov 18 · Rule based · BackgroundBackgroundBetamethasone ValerateIntervention entry›Nov 18 · Rule based · BackgroundBackgroundFluticasoneEntry “Fluticasone Propionate”, read …›Nov 18 · Rule based · BackgroundBackground

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Dupilumab

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Dupilumab”the record gives no role
→judged→changed
How the 2 judgments split50%of judgments with a known value say Tested
Tested · 1
Background · 1

All judgments on this study

WhenLinkJudgeDecisionState
Nov 4DupilumabClaude Opus 5.5TestedCurrent
Nov 18Squaric acid dibutyl esterRule based · role ruleBackgroundCurrent
Nov 18DupilumabRule based · role ruleBackgroundOverridden
Nov 18AdalimumabRule based · role ruleBackgroundCurrent
Nov 18UstekinumabRule based · role ruleBackgroundCurrent
Nov 18GuselkumabRule based · role ruleBackgroundCurrent
Nov 18CanakinumabRule based · role ruleBackgroundCurrent
Nov 18SarilumabRule based · role ruleBackgroundCurrent
Nov 18Triamcinolone AcetonideRule based · role ruleBackgroundCurrent
Nov 18Betamethasone ValerateRule based · role ruleBackgroundCurrent
Nov 18FluticasoneRule based · role ruleBackgroundCurrent
As of nowDermatitis, Allergic ContactRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.